There is general agreement that mental illnesses result from a complex interplay of genetic and environmental factors. But decidedly more effort has gone into understanding the genetic side of the equation than the environmental one. Read More
The CIMBA consortium, led by researchers from the University of Pennsylvania, has analyzed more than 30,000 carriers of mutations in the breast cancer risk genes BRCA1 and BRCA2 and identified "cluster regions" in which mutations were more likely to lead to cancer. Read More
Bionomics Ltd., of Adelaide, Australia, said it will present a poster with new data on the DisrupTOR-1 trial of the vascular disrupting agent BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit in Shanghai. Read More
Forward Pharma A/S, of Copenhagen, Denmark, disclosed an agreement among all of its pre-IPO shareholders to voluntarily lock-up their shares for an additional 365 days beyond the expiration of the original IPO lock-up. Read More
LONDON – After plateauing in February and early March, the number of new Ebola cases is falling again, decreasing the likelihood of getting meaningful results from ongoing phase III vaccines trials in affected countries, according to the latest assessment by World Health Organization (WHO) Assistant Director General Bruce Aylward. Read More
As the curtain closed on the first quarter of the year, the report card performance numbers weren’t pretty, as ongoing energy price ebbs and flows coupled with mixed domestic economic data kept the general markets on edge. As a result, the Dow Jones Industrial Average closed flat for the quarter and down 1.2 percent for the month of March. Read More
Partnering with patient advocacy organizations is an increasingly attractive avenue to speed drugs for rare indications into clinical development. For the smallest of biotechs, the strategy also can keep a company afloat. Read More
Inmed Pharmaceuticals Ltd., a Canadian-listed start-up mixing cannabinoids and noncannabis elements for the treatment of glaucoma, pain and inflammation is working to move into the clinic this year and attract the kind of big pharma backers that have rallied to support high-profile cannabinoid drugmaker GW Pharmaceuticals plc. Read More
Karo Bio AB, of Stockholm, acquired all of the shares of drug research company Tanomed AB, of Umea, Sweden, which developed a product in collaboration with the University of Umea to treat the common cold by reinforcing the body’s own defenses. Read More
